Mechanism

Helminthic therapy operates through several converging mechanisms relevant to this patient’s inflammatory picture.

Primary effects: Th2 immune skewing and regulatory T-cell induction directly dampen the Th1/Th17 inflammatory response that drives RA pathology. This is not suppression. It is immune retraining toward a regulatory rather than inflammatory predominance. These effects operate systemically, independent of gut environment.

Mucosal effects: In a normal or moderately dysbiotic gut, helminth colonization reinforces intestinal barrier integrity and modulates microbiome composition. These mucosal effects are meaningful under those conditions. Whether they were operating meaningfully during 2024–2025 depends on the severity of dysbiosis actually present during that period — Thorne testing at the time showed Proteobacteria dominance at the 99.9th percentile and negligible commensal populations, which would have left little substrate for HT’s mucosal mechanisms to work with. As of August 2026, current-state testing (Jona, Biomesight) no longer shows that architecture, and the locked-dysbiosis hypothesis is under reassessment (see Iron Dysbiosis reference, III-c). Whether HT’s mucosal contribution has changed accordingly is not something current data addresses directly — no HT-specific efficacy reassessment has been done against the 2026 gut testing.

Possible vagal effects: Animal data supports helminth colonization increasing vagal tone through gut-vagus signaling pathways. Whether this effect is meaningful in a system with the degree of vagal deficit documented in this patient is uncertain.

Clinical Response 2020–2023

The initial recovery from Class IV functional status, bedridden except for medical visits, was driven by high-dose prednisone over several months, not by HT. Prednisone broke the inflammatory momentum that had built to that level. The system restabilized at a functional baseline from which ongoing management became possible. This is consistent with the reset dynamic documented in the Pharmacological Phenotype reference.

HT was initiated after biologic failures, into a system that had been partially stabilized by prednisone but continued to experience ongoing flares and structural damage. Its contribution was to tone down that ongoing activity and make full functional status achievable. It did not rescue from crisis. It provided the sustained immune regulatory tone that pharmaceuticals had not been able to maintain.

The response was substantial and sustained across approximately three years. Microscopic colitis symptoms resolved and remained absent for four years. The underlying condition persisted on biopsy throughout, as confirmed by the December 2025 colonoscopy, but was asymptomatic.

Inflammatory markers improved markedly. CRP fell from a peak of 11.2 to consistently 1.2–2.5 mg/L. ESR improved though did not normalize. Food reactivity reduced substantially. Anti-CCP was notably negative in May 2023, during the period of strongest HT response.

Structural joint destruction appeared to slow dramatically during this period. The 2026 MRI findings document rapid acceleration of damage following the 2024 escalation, which by contrast confirms the stabilizing effect HT had provided.

The medication-sparing effect was significant. PRN pharmaceutical use was minimal throughout this period.

The 2024 Escalation and Change in Apparent Effect

The iron infusions in late 2023 and early 2024 preceded a major systemic escalation. NA colonization was never interrupted during this period — it has remained continuous since 2020, including through this escalation and through the unrelated July 2024 antihelminthic treatment of a co-occurring organism, after which NA was reestablished immediately. There is no window in which a reduction in worm burden could explain any change in HT’s apparent effect.

HT’s own regulatory mechanisms — Th2 skewing, regulatory T-cell induction, dampening of Th1/Th17 activity — have no basis for having weakened on their own. The more coherent explanation is that the inflammatory and barrier-permeability load these mechanisms are working against increased following the iron infusions, not that HT’s contribution diminished. The same brake, applied to a larger problem, produces less visible stabilization without the brake itself failing.

This has a direct practical consequence: increasing HT dosing, or adding additional worms, would not address the actual driver. If the escalation reflects increased upstream immune/barrier load rather than insufficient Th2/Treg signal, more worms would treat the wrong side of the equation. Dosing has not been increased for this reason.

RA activity converted from episodic flares to a continuous baseline inflammatory state. Microscopic colitis symptoms returned after four years of remission. Structural joint destruction accelerated markedly, documented objectively in the 2026 MRI series. These are real, independent clinical facts regardless of which explanation for the underlying gut/immune mechanism proves correct.

Current Status

HT remains in active use and is considered necessary. Discontinuation produces rapid measurable functional deterioration, and this necessity has been demonstrated repeatedly rather than assumed. This is continuous active intervention maintaining a baseline lower than 2020–2023, not achieved stability.

The current picture is a system in which HT continues to provide real regulatory input against a larger inflammatory/barrier load than it faced 2020–2023 — not a system in which HT itself has become less effective. Whether the increased load is still connected to the originally hypothesized locked gut state is unresolved and, per the current-state gut testing (III-c), not the most likely explanation; the load may be driven by ongoing barrier dysfunction, systemic inflammatory processes, or both, independent of any specific microbiome architecture.

Relationship to VNS

HT and vagus nerve stimulation address the same underlying regulatory deficit from different directions and are not redundant.

HT provides systemic immune modulation through Th2 skewing and regulatory T-cell induction. Its apparent stabilizing effect since 2024 has been reduced relative to 2020–2023 — better explained by an increased inflammatory/barrier load than by any change in HT’s own activity (see above); the extent to which gut-specific mechanisms versus broader systemic load are driving that increase is an open question (see III-c).

VNS works through direct electrical stimulation of the efferent vagal arc, bypassing the damaged and fatigued endogenous pathway, suppressing NF-κB-driven cytokine transcription through the cholinergic anti-inflammatory pathway. Its effects are direct and independent of gut environment.

Neither addresses gut barrier dysfunction directly. They are parallel interventions on different components of the same regulatory circuit. The increased load HT has been working against since the 2024 escalation does not predict anything about VNS efficacy, since VNS bypasses the gut environment entirely.